Pulse BiosciencesPLSE
About: Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled. Substantial revenue is generated from North America Majorly due to the sale of systems.
Employees: 56
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
86% more call options, than puts
Call options by funds: $1.75M | Put options by funds: $941K
76% more repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 17
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
5% more capital invested
Capital invested by funds: $98.6M [Q3] → $104M (+$5.16M) [Q4]
0.55% more ownership
Funds ownership: 9.18% [Q3] → 9.73% (+0.55%) [Q4]
0% more funds holding
Funds holding: 72 [Q3] → 72 (+0) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for PLSE.
Financial journalist opinion
Based on 5 articles about PLSE published over the past 30 days









